<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02509806</url>
  </required_header>
  <id_info>
    <org_study_id>Ahead-G309</org_study_id>
    <nct_id>NCT02509806</nct_id>
  </id_info>
  <brief_title>Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hebei Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of apatinib as maintenance&#xD;
      therapy after first-line chemotherapy in Postoperative Recurrence / Metastasis Progressive&#xD;
      Gastric Cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will receive apatinib treatment(500mg qd p.o. q28d) until until disease&#xD;
      progression or intolerable toxicity or patients withdrawal of consent after 4 cycles of DC&#xD;
      first-line chemotherapy or only DC first-line chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>An expected average of 12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Apatinib Maintenance Therapy After First-line Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib Mesylate Tablets 500 mg qd p.o. after DC First-line Chemotherapy (Docetaxel 60-85mg/m2 i.v. d1, Cisplatin 60-75mg/m2 i.v. d1, q21d）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Intervention After First-line Chemotherapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No Intervention after DC First-line Chemotherapy (Docetaxel 60-85mg/m2 i.v. d1, Cisplatin 60-75mg/m2 i.v. d1, q21d）</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib Mesylate Tablets 500 mg qd p.o.</description>
    <arm_group_label>Apatinib Maintenance Therapy After First-line Chemotherapy</arm_group_label>
    <other_name>ATAN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 18 to75 years old;&#xD;
&#xD;
          2. Histologically proven progressive gastric cancer. All pts were received D2 gastrectomy&#xD;
             and recurrence / metastasis occured;&#xD;
&#xD;
          3. Complete 4 cycles DC first-line chemotherapy and no and no disease progression&#xD;
             occurred. DC: Docetaxel 60-85mg/m2 iv d1, Cisplatin 60-75mg/m2 iv d1, q21d;&#xD;
&#xD;
          4. ECOG PS of 0-1;&#xD;
&#xD;
          5. Major organ function has to meet the following criteria:&#xD;
&#xD;
             ANC ≥ 1.5 × 109 / L; HB ≥ 90g / L; PLT ≥ 100 × 109 / L; Bilirubin &lt;1.5 times the upper&#xD;
             limit of normal (ULN); ALT and AST &lt;2.5 × ULN; liver metastases, if any, the ALT and&#xD;
             AST&lt;5 × ULN;&#xD;
&#xD;
          6. An expected survival of ≥ 3 months;&#xD;
&#xD;
          7. Pregnancy test (serum or urine) has to be performed for woman of childbearing age&#xD;
             within 7 days before enrolment and the test result must be negative. They shall take&#xD;
             appropriate methods for contraception during the study until the 8th week post the&#xD;
             last administration of study drug. For men, (previous surgical sterilization&#xD;
             accepted), shall agree to take appropriate methods of contraception during the study&#xD;
             until the 8th week post the last administration of study drug.&#xD;
&#xD;
          8. Patient has to voluntarily join the study and sign the Informed Consent Form for the&#xD;
             study;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Confirmed that apatinib and/or its accessories allergy;&#xD;
&#xD;
          2. Subjects with poor-controlled arterial hypertension (systolic blood pressure&gt; 140 mmHg&#xD;
             and diastolic blood pressure &gt; 90 mm Hg) despite standard medical management; Coronary&#xD;
             heart disease greater than ClassI; I-level arrhythmia (including QT interval&#xD;
             prolongation, for man ≥ 450 ms, for woman ≥ 470 ms) together with Class II cardiac&#xD;
             dysfunction;&#xD;
&#xD;
          3. Factors that could have an effect on oral medication (such as inability to swallow,&#xD;
             chronic diarrhea and intestinal obstruction);&#xD;
&#xD;
          4. Subjects with high gastrointestinal bleeding risk, including the following conditions:&#xD;
             local active ulcer lesions with positive fecal occult blood test (++); history of&#xD;
             black stool, or vomiting blood in the past 2 months;&#xD;
&#xD;
          5. Abnormal Coagulation (INR&gt;1.5、APTT&gt;1.5 UNL), with tendency of bleed;&#xD;
&#xD;
          6. Associated with CNS (central nervous system) metastases;&#xD;
&#xD;
          7. Pregnant or lactating women;&#xD;
&#xD;
          8. Pts with other malignant tumor within 5 years(except cured skin basal cell carcinoma&#xD;
             and cervical carcinoma);&#xD;
&#xD;
          9. With psychotropic drug abuse history and can't get rid of or mental disorder patients;&#xD;
&#xD;
         10. Participated in other clinical trials within 4 weeks.&#xD;
&#xD;
         11. Pts received VEGFR inhibitor treatment(i.e. sorafenib, sunitinib);&#xD;
&#xD;
         12. Any other condition that might place the patient at undue risk or preclude a patient&#xD;
             from completing the study;&#xD;
&#xD;
         13. Other conditions regimented at investigators' discretion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhao Qun, MD</last_name>
    <phone>0311-86543035</phone>
    <email>zhaoqun516@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fourth Affiliated Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Zhao Qun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>July 26, 2015</study_first_submitted>
  <study_first_submitted_qc>July 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2015</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University</investigator_affiliation>
    <investigator_full_name>Qun Zhao</investigator_full_name>
    <investigator_title>Principal Investgator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

